Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Clinical trial NCT05313243 · RECRUITING
Trial details
- NCT number
- NCT05313243
- Sponsor
- Yale University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-10
- Primary completion
- 2028-04-30
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.